 This study demonstrated the potential of using hematopoietic stem and progenitor cells, HSBCs, to treat the severe CLN1 neurodegenerative disorder. The researchers found that transplantation of wild type HSBCs was able to partially alleviate symptoms of the disease, while transplantation of HSBCs over expressing the enzyme responsible for the disease, PPT1, resulted in a more significant improvement in symptoms. Additionally, they were able to demonstrate the effectiveness of transplantation of HSBCs via two different routes, intravenously and in traceribroventricularly, suggesting that this method could be used as a viable treatment option for patients suffering from CLN1 disease. This article was authored by Marco Peviani, Sopya Sochi Das, John Key Patel, and others.